# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
The Company recently became aware of the rapid accumulation of a significant amount (19.3%) of the common stock of the Company ...
AN2 Therapeutics (NASDAQ:ANTX) reported quarterly losses of $(0.48) per share which beat the analyst consensus estimate of $(0....
AN2 Therapeutics reported topline results from the Phase 2/3 EBO-301 study of epetraborole in treatment-refractory MAC lung dis...
JMP Securities analyst Roy Buchanan maintains AN2 Therapeutics (NASDAQ:ANTX) with a Market Outperform and lowers the price t...
EBO-301 study to be discontinued following topline results from Phase 2 part of the study in treatment-refractory patients with...
Leerink Partners analyst Joseph Schwartz upgrades AN2 Therapeutics (NASDAQ:ANTX) from Market Perform to Outperform.